Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma
Man Liu(University of Minnesota), John Wong(Chinese University of Hong Kong), Otto Ka-Wing Cheung(Chinese University of Hong Kong), Jingying Zhou(Ningbo University Affiliated Hospital), Stephen L. Chan(Chinese University of Hong Kong), Joseph J.�Y. Sung(Nanyang Technological University), Ka‐Fai To(Chinese University of Hong Kong), Xuezhen Zeng(Sun Yat-sen University), Myth T.S. Mok(Chinese University of Hong Kong), Wenshu Tang(Chinese University of Hong Kong), Philip Chun Yeung(Chinese University of Hong Kong), Hongchuan Jin(Sir Run Run Shaw Hospital), Jie Chen(Jiangsu University), Zhiwei Chen(Fujian Medical University), Xiaoyu Liu(Shanghai Ninth People's Hospital), Feng Wu(Nantong University), Yu Feng(Central South University of Forestry and Technology), Weiqin Yang(Chinese University of Hong Kong), Minhu Chen(Sun Yat-sen University), Anthony W.H. Chan(Chinese University of Hong Kong), Paul B.S. Lai(Chinese University of Hong Kong), Hanyong Sun(Shanghai Jiao Tong University)
Cited by 182
Related Papers
Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study
|The Lancet Infectious Diseases|2020|3.4k
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations
|Nature Genetics|2015|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k